Australia Molecular Diagnostics Market (2025-2030)
The Australia Molecular Diagnostics Market was valued at $91.8 Million in 2025 and projected to reach to $149.9 Million by 2030, representing a compound annual growth rate of 10.3%. Australia's molecular diagnostics market is positioned for sustained expansion, driven by the country's commitment to healthcare innovation and increasing prevalence of chronic diseases requiring molecular-level diagnosis.
Australia Molecular Diagnostics Market Trends and Insights
- This 10.3% compound annual growth rate reflects Australia's strong healthcare infrastructure, increasing adoption of precision medicine, and rising demand for rapid diagnostic solutions across infectious disease, oncology, and genetic testing sectors.
- Australia's investment in advanced laboratory technologies and regulatory support for molecular testing platforms are driving market expansion. The Australian molecular diagnostics landscape is characterized by growing clinical adoption in both public and private healthcare settings.
- Australia's aging population and prevalence of chronic diseases are accelerating demand for molecular testing capabilities.
- Between 2025 and 2030, Australia is expected to see significant growth in point-of-care molecular testing, liquid biopsy applications, and personalized medicine initiatives, supported by government healthcare funding and private sector innovation..
Key Market Statistics
- CAGR (2025-2030) 10.3% CAGR
- Market Size, 2025 ~USD 91.8 Million
- Forecast, 2030 ~USD 149.9 Million
- Country Australia
Australia Molecular Diagnostics Market Overview
Market Valuation Growth :
Australia's molecular diagnostics market is valued at USD 91.8 million in 2025, with strong momentum projected to reach USD 149.9 million by 2030, representing a robust 10.3% CAGR.
Advanced Healthcare Infrastructure :
Australia's world-class healthcare system and high adoption rates of advanced diagnostic technologies create a favorable environment for molecular diagnostics expansion across major metropolitan and regional centers.
Precision Medicine Adoption :
Increasing integration of precision medicine in Australian clinical practice, particularly in oncology and genetic testing, is driving demand for sophisticated molecular diagnostic solutions among healthcare providers.
Rapid Diagnostic Solutions Demand :
Rising demand for quick turnaround molecular tests in infectious disease management, cancer diagnostics, and hereditary condition screening is accelerating market growth across Australian laboratories and hospitals.
Australia Molecular Diagnostics Market Dynamics
- The 10.3% CAGR significantly outpaces the global average of 9.6%, reflecting Australia's advanced healthcare infrastructure and strong adoption of precision medicine practices.
- Key growth drivers include rising investments in diagnostic infrastructure, growing awareness of early disease detection benefits, and expanding genomic testing capabilities across public and private healthcare sectors.
- The market is expected to benefit from increased government funding for diagnostic services and growing collaboration between research institutions and diagnostic providers, solidifying Australia's position as a leader in molecular diagnostics within the Asia-Pacific region..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Stryker Corporation
- Abbott Laboratories
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- Australia's molecular diagnostics market will grow from USD 91.8M (2025) to USD 149.9M (2030) at a 10.3% CAGR.
- Australia's advanced healthcare infrastructure and regulatory environment support rapid adoption of molecular testing technologies.
- Australia's aging population and chronic disease burden are key drivers of molecular diagnostics demand through 2030.
- Australia is experiencing increased investment in precision medicine and point-of-care molecular testing platforms.
Molecular Diagnostics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | HEPATITIS (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 9.6% from 2025 to 2030 |
| Largest Segment | LAB TESTS (Test Type) |
| Market Size Base Year (Billions) | ~USD 19.44 (2025) |
| Revenue Forecast (Billions) | ~USD 30.74 (2030) |
| Segments Covered | Product & Service, Test Type, Sample Type, Type |
Australia Molecular Diagnostics Market Report Segmentation
4 segment dimensions are covered across the global market.
By Product & Service
- Instruments
- Reagents & Kits
- Services & Software
By Test Type
- Lab Tests
- Poc Tests
By Sample Type
- Blood, Serum & Plasma
- Other Sample Types
- Urine
By Type
- Breast Cancer
- Colorectal Cancer
- Influenza
- Lung Cancer
- Other Cancers
- Other Respiratory Infectious Diseases
- Pharyngitis
- Prostate Cancer
- Tuberculosis
Target Audience
- Diagnostic Equipment Manufacturers : Manufacturers need Australia-specific market data to assess demand for molecular diagnostic platforms, understand local purchasing preferences, and develop go-to-market strategies for the high-growth Australian healthcare sector.
- In Vitro Diagnostics (IVD) Companies : IVD companies require detailed Australian market insights to identify growth opportunities in molecular assays, optimize product portfolios for local clinical needs, and navigate Australia's stringent regulatory approval processes.
- Healthcare Investment Firms : Investment professionals need Australia-focused market analysis to evaluate acquisition targets, assess growth potential of diagnostic service providers, and identify emerging opportunities in precision medicine and genomic testing.
- Pathology Laboratory Networks : Australian pathology providers need market intelligence to benchmark performance, identify service expansion opportunities, plan capital investments in molecular infrastructure, and respond to competitive pressures in their regions.
- Healthcare Policy & Government Bodies : Government agencies and health policy makers require market data to inform funding decisions, develop diagnostic service strategies, assess healthcare technology adoption, and plan public health initiatives around molecular testing.
Key Companies in the Australia Molecular Diagnostics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | GeneXpert instruments,Xpert test cartridges (infectious disease and HAIs),Virology, oncology, and genetics assays, |
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, logistics, O&M, mission-critical facilities), |
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CODEXIS, INC. | United States | Public Company | CodeEvolver-enabled enzyme products and services,ECO Synthesis RNAi manufacturing platform (licenses, milestones, royalties),Other technology partnerships and R&D collaborations, |
| UNILABS | Switzerland | Private Company | Core laboratory testing,Medical imaging,Pathology and centres of excellence, |
| EIKEN CHEMICAL CO., LTD. | Japan | Public Company | Fecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and media (clinical),Urinalysis test strips, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology,Life Sciences,Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array instruments and consumables, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, localization, treatment support),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa ProVu, CoolSeal), |
| BIOMÉRIEUX | France | Public Company | |
| ABBOTT LABORATORIES | United States | Public Company | Medical Devices (cardiovascular, diabetes care, neuromodulation),Diagnostic Products (lab, molecular, point-of-care, rapid),Nutritional Products (pediatric, adult, infant formula), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Immune response (TB and transplant/viral load assays),Oncology and sexual and reproductive health assays, |
| REVVITY, INC. | United States | Public Company | Diagnostics (prenatal, neonatal, infectious disease, autoimmune),Life science reagents and assay platforms,Instruments, software, and services, |
| GRIFOLS, S.A. | Spain | Public Company | Biopharma (plasma-derived medicines),Diagnostic,Bio Supplies, |
CEPHEID INC.
Cepheid Inc. is a private U.S. diagnostic company founded in 1996 with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing solutions.
FLUOR CORPORATION
Fluor Corporation is a large U.S. engineering and construction company founded in 1912, operating as a public company with approximately 23,000 employees. The firm provides design, engineering, procurement, and construction services across multiple industries.
SANOFI
Sanofi is a major French pharmaceutical company founded in 1994 and publicly traded, with over 74,800 employees worldwide. The company develops and manufactures prescription medicines, vaccines, and consumer healthcare products.
CODEXIS, INC.
Codexis, Inc. is a publicly traded U.S. biotechnology company founded in 2002 with 146 employees. The company develops and commercializes biocatalysts and enzymes for pharmaceutical and chemical manufacturing.
UNILABS
Unilabs is a private Swiss clinical laboratory and diagnostics company founded in 1987 with 1,897 employees. The company offers laboratory testing and diagnostic services across Europe.
EIKEN CHEMICAL CO., LTD.
Eiken Chemical Co., Ltd. is a publicly traded Japanese chemical and diagnostics company founded in 1939 with 696 employees. The company manufactures diagnostic reagents, pharmaceuticals, and chemical products.
DANAHER CORPORATION
Danaher Corporation is a large publicly traded U.S. conglomerate founded in 1969 with 59,000 employees. The company operates across multiple sectors including diagnostics, life sciences, and environmental solutions.
ILLUMINA, INC.
Illumina, Inc. is a publicly traded U.S. genomics company founded in 1998 with 8,625 employees. The company designs and manufactures DNA sequencing and array-based analysis systems.
HOLOGIC, INC.
Hologic, Inc. is a private U.S. medical device company founded in 1985 with 7,070 employees. The company develops and manufactures diagnostic and surgical products focused on women's health and oncology.
BIOMÉRIEUX
bioMérieux is a publicly traded French diagnostics company founded in 1963 with 14,894 employees. The company specializes in in vitro diagnostics for infectious diseases, industrial microbiology, and food safety.
ABBOTT LABORATORIES
Abbott Laboratories is a large publicly traded U.S. healthcare company founded in 1888 with 115,000 employees. The company manufactures pharmaceuticals, diagnostics, medical devices, and nutritional products.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a major publicly traded U.S. life sciences company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, software, and services for research and diagnostics.
QIAGEN N.V.
QIAGEN N.V. is a publicly traded Dutch life sciences company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics, sample preparation, and bioinformatics solutions.
REVVITY, INC.
Revvity, Inc. is a publicly traded U.S. life sciences and diagnostics company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for research and diagnostics.
GRIFOLS, S.A.
Grifols, S.A. is a publicly traded Spanish pharmaceutical and diagnostics company founded in 1909 with 25,000 employees. The company specializes in plasma-derived medicines, transfusion medicine, and diagnostics.
Reasons to Buy this Report
- Market-Specific Growth Projections : Access detailed forecasts showing Australia's molecular diagnostics market expanding from USD 91.8M to USD 149.9M by 2030, enabling accurate business planning and investment decisions tailored to the Australian market.
- Competitive Landscape Intelligence : Understand the competitive dynamics specific to Australia's healthcare sector, including key players, market consolidation trends, and strategic positioning opportunities within the country's regulated diagnostic environment.
- Regulatory & Reimbursement Insights : Gain comprehensive understanding of Australia's unique regulatory framework, NATA accreditation requirements, Medicare reimbursement policies, and pathology funding models that directly impact market entry and profitability.
- Technology Adoption Trends : Identify which molecular diagnostic technologies are gaining traction in Australian laboratories, hospitals, and private practices, including NGS, PCR, and digital pathology adoption rates specific to the region.
- Strategic Partnership Opportunities : Discover potential collaboration and distribution opportunities with Australian healthcare providers, diagnostic laboratories, and research institutions positioned to capitalize on the 10.3% CAGR growth trajectory.
Frequently asked questions
What is the current size of Australia's molecular diagnostics market?
Australia's molecular diagnostics market is valued at USD 91.8 million in 2025 and is projected to reach USD 149.9 million by 2030.
What is the growth rate of Australia's molecular diagnostics market?
Australia's molecular diagnostics market is growing at a compound annual growth rate (CAGR) of 10.3% from 2025 to 2030.
What factors are driving growth in Australia's molecular diagnostics market?
Key drivers include Australia's aging population, increasing prevalence of chronic diseases, strong healthcare infrastructure, regulatory support, and growing adoption of precision medicine and point-of-care testing.
Which segments are growing fastest in Australia's molecular diagnostics market?
Australia is experiencing rapid growth in infectious disease testing, oncology diagnostics, genetic testing, liquid biopsy applications, and point-of-care molecular testing platforms.
How does Australia's molecular diagnostics market compare to the Asia Pacific region?
Australia's 10.3% CAGR outpaces the global average of 9.6%, reflecting strong market fundamentals, healthcare investment, and technological adoption within the country.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global molecular diagnostics market. Exhaustive secondary research was done to collect information on the molecular diagnostics market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the molecular diagnostics market.
The four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to, to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources mainly include industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
Breakdown Of Primary Participants
Note 1: Others include Sales Managers, Marketing Managers, and Product Managers.
Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers:
Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate and validate the molecular diagnostics market’s total size. These methods were also used extensively to estimate the size of various subsegments in the market.
- The key players in the industry have been identified through extensive secondary research.
- Primary and secondary research have determined the revenues generated by leading players operating in the molecular diagnostics market.
- All percentage share, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Molecular diagnostics is a technique used to identify and analyze nucleic acids or proteins at a molecular level. This technique assesses an individual’s genetic makeup to identify a predisposition to any particular disease or condition and diagnose it.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global molecular diagnostics market by product & service, test type, sample type, technology, application, technique, clinical application, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To analyze the micromarkets concerning individual growth trends, prospects, and contributions to the overall molecular diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market with respect to five regions, namely North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments, such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the molecular diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the molecular diagnostics market, along with the macroeconomic outlook for each region
Get the Full Molecular Diagnostics Market Report
Full forecast, segment splits, and company analysis for all Molecular Diagnostics Market.
- Canada Molecular Diagnostics Market
- US Molecular Diagnostics Market
- Germany Molecular Diagnostics Market
- UK Molecular Diagnostics Market
- France Molecular Diagnostics Market
- Italy Molecular Diagnostics Market
- Spain Molecular Diagnostics Market
- Russia Molecular Diagnostics Market
- Switzerland Molecular Diagnostics Market
- China Molecular Diagnostics Market
- Japan Molecular Diagnostics Market
- India Molecular Diagnostics Market
- South Korea Molecular Diagnostics Market
- Brazil Molecular Diagnostics Market
- Mexico Molecular Diagnostics Market
- Saudi Arabia Molecular Diagnostics Market
- UAE Molecular Diagnostics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report